Welcome to Markets Desk, here's what's moving the tape this hour.
Liquidia Corporation surged after announcing a global settlement with United Therapeutics, resolving all six pending litigation matters between the two companies. For Liquidia, this clears a significant legal overhang that had weighed on its path to commercializing its pulmonary hypertension treatment, and the market responded accordingly with shares climbing sharply on the news.
Shifting to pharma and legal risk, CVS Health has agreed to pay three hundred fifteen million dollars to settle federal allegations that its pharmacy units unlawfully dispensed opioids and other controlled substances while submitting false claims to federal healthcare programs. It's another costly chapter in the industry-wide reckoning over opioid distribution, and adds further pressure to CVS as it navigates an already difficult operating environment.
On the macro front, New York Federal Reserve President John Williams signaled that the artificial intelligence buildout is creating a supply squeeze he expects to persist well beyond two years, and he reaffirmed his view that the Fed may need to raise interest rates at least one more time this cycle. That combination of structural inflation pressure and a hawkish lean kept bond traders on edge heading into the close.
That's the tape. Markets Desk, signing off the floor.
